Biofield U.S. trials for non-invasive breast cancer diagnosis system to wrap up in 1996.
This article was originally published in The Gray Sheet
Executive Summary
BIOFIELD NON-INVASIVE BREAST CANCER DIAGNOSTIC SYSTEM U.S. TRIALS are expected to be completed during 1996, the company says in a prospectus for an initial public offering. Initiated in March 1995, the six-center study is slated to involve 1,300 women with suspicious lesions detected by x-ray mammography or physical examination. Data from the trial will form the basis of a premarket approval application, which FDA has pledged to review on an expedited basis. The study is being conducted under approval from hospital investigational review boards, which deemed the product a non-significant risk device, the prospectus reports.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.